| Dr Patricia Maran, MD | |
|
17 & Chew St, Lehigh Valley Hospital, Allentown, PA 18105-7017 | |
| (610) 969-4515 | |
| Not Available |
| Full Name | Dr Patricia Maran |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 20 Years |
| Location | 17 & Chew St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760690275 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD433291 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Health Partners Community Health Center | 4284065327 | 59 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
Rogers Behavioral Health System, Wisconsin's largest, not-for-profit mental health and addiction services provider, is opening its first treatment center outside of Wisconsin in Tampa, Fla., on Monday, September 29.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 1 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
Rogers Behavioral Health System, Wisconsin's largest, not-for-profit mental health and addiction services provider, is opening its first treatment center outside of Wisconsin in Tampa, Fla., on Monday, September 29.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 1 days ago
| Entity Name | Valley Health Partners Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770118648 PECOS PAC ID: 4284065327 Enrollment ID: O20200505003199 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
Rogers Behavioral Health System, Wisconsin's largest, not-for-profit mental health and addiction services provider, is opening its first treatment center outside of Wisconsin in Tampa, Fla., on Monday, September 29.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patricia Maran, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: (484) 884-4500 | Dr Patricia Maran, MD 17 & Chew St, Lehigh Valley Hospital, Allentown, PA 18105-7017 Ph: (610) 969-4515 |
News Archive
Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.
Rogers Behavioral Health System, Wisconsin's largest, not-for-profit mental health and addiction services provider, is opening its first treatment center outside of Wisconsin in Tampa, Fla., on Monday, September 29.
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.
Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 1 days ago
Dr. Rachel O'connell, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 501 Cetronia Rd Ste 120, Allentown, PA 18104 Phone: 845-262-5204 | |
Treasure Ngozi Ada Walker, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1245 S Cedar Crest Blvd Ste 201, Allentown, PA 18103 Phone: 610-402-4870 Fax: 610-402-4960 | |
Dr. Timothy M Pellini, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1245 S Cedar Crest Blvd, Suite 201, Allentown, PA 18103 Phone: 610-437-1931 Fax: 610-433-8791 | |
Shirin Azadi, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1627 Chew St, Allentown, PA 18102 Phone: 610-402-6000 | |
Dr. Salam Syed, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-8000 | |
Jennifer Melanie Heibig, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-5100 | |
Dahlia Kronfli, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1628 Chew St, Allentown, PA 18102 Phone: 610-402-1600 |